PNC-27
Longevity & Cellular HealthAlso known as: p53-Penetratin Chimeric Peptide, Anti-Cancer Peptide PNC-27
Mechanism
PNC-27 is an anticancer peptide that selectively kills cancer cells while leaving normal cells completely unharmed. It works by targeting a protein called HDM-2 that is found on the surface membranes of cancer cells but not normal cells. When PNC-27 binds to membrane-bound HDM-2, it punches holes in the cancer cell membrane, causing the cell to die by necrosis. It has shown activity against a wide range of cancers including breast, pancreatic, lung, colon, and leukemia — all in laboratory settings. It does not require functional p53 in the cancer cell to work.
Technical detail
PNC-27 is a chimeric peptide containing an HDM-2-binding domain (residues 12-26 of p53) fused to a cell-penetrating peptide (penetratin) domain. It targets HDM-2 (human double minute 2, the human homolog of MDM2) that is aberrantly expressed on the plasma membranes of cancer cells but absent from normal cell membranes. Binding of PNC-27 to membrane-bound HDM-2 induces formation of transmembrane pore complexes, leading to rapid tumor cell necrosis (membranolysis). The 3D structure of PNC-27's p53 domain is directly superimposable on the p53 residues bound to HDM-2 in crystal structures. Also enters cancer cells and disrupts mitochondrial membranes. Cytotoxicity is independent of cellular p53 status — effective against p53-null cancer lines. Published in PNAS (Kanovsky et al., 2010) and Biomedicines.
Effects
ONCOLOGICAL: Primary and essentially sole application. Selectively kills cancer cells while leaving normal cells completely unharmed — one of the most cancer-selective compounds known. Mechanism: targets HDM-2 (human double minute 2, the human MDM2 homolog) that is aberrantly expressed on the PLASMA MEMBRANES of cancer cells. Normal cells express HDM-2 only intracellularly; cancer cells translocate it to the membrane surface. When PNC-27 binds membrane-bound HDM-2, it forms transmembrane pore complexes → rapid necrosis (cell membrane lysis). Published in PNAS (Kanovsky et al., 2010): structure of PNC-27's p53 domain is directly superimposable on p53 residues bound to HDM-2 in crystal structures. Effective against: breast (MCF-7, MDA-MB-231), pancreatic (PANC-1), lung (A549), colon (HT-29), ovarian, and leukemia (K562, HL-60, U937) cell lines in vitro. Also enters cancer cells and disrupts mitochondrial membranes — dual kill mechanism. Critical: cytotoxicity is INDEPENDENT of p53 status — effective against p53-null and p53-mutant cancers (this is huge because ~50% of all cancers have p53 mutations). Transfecting normal cells with membrane-targeted HDM-2 makes them susceptible to PNC-27 — proving the membrane-HDM-2 targeting mechanism (Sookraj et al., 2010). Does not bind soluble HDM-2 — only membrane-bound form — explaining tumor selectivity. IMMUNE: Induces immunogenic cell death (necrosis releases DAMPs that may stimulate anti-tumor immune response — theoretical). No immunosuppressive effects observed. No effects on normal immune cells at effective anti-cancer concentrations. OTHER SYSTEMS: No known effects on cardiovascular, neurological, musculoskeletal, endocrine, or metabolic systems — this is a cancer-specific tool. Tier 3: Very limited practitioner use due to research-only status and high cost. Some integrative oncology practitioners have explored it in compassionate use settings (anecdotal, not published).
Practitioner Guide
DOSING TIPS: NO established human dosing protocol. All data is from in-vitro and animal studies. In cell culture: effective concentrations range from 50-200 µM depending on cancer type. Animal studies have used intraperitoneal and intratumoral injection. Some experimental protocols use 1-5 mg/kg in animal models. THIS IS NOT READY FOR CLINICAL USE — included for educational completeness. RECONSTITUTION: Research-grade lyophilized peptide — reconstitute with sterile water or PBS for laboratory use. Not available from compounding pharmacies in clinical-grade formulations. IMPORTANT CAVEATS: (1) In-vitro efficacy does not guarantee in-vivo efficacy — tumor microenvironment, peptide stability in blood, biodistribution, and tissue penetration are all unknown. (2) No pharmacokinetic data in humans. (3) Peptide may be degraded rapidly in circulation — delivery optimization needed. (4) Cost is very high due to synthesis complexity (chimeric peptide with penetratin domain). RESEARCH CONTEXT: This peptide is genuinely scientifically exciting — the selectivity for cancer cells over normal cells is remarkable and well-characterized. The mechanism (membrane-bound HDM-2 targeting) is novel and published in top journals (PNAS). However, the gap between in-vitro data and clinical application is enormous. SUPPLEMENT SYNERGIES: Ketone bodies may enhance PNC-27 cytotoxicity — a 2024 study showed that combining PNC-27 with ketone bodies increased killing of cervical cancer cells (Medical Research Archives). CONTRAINDICATION NUANCES: Unknown — no human data. Peptides with cell-penetrating domains (penetratin) can theoretically enter any cell type, but specificity is conferred by the HDM-2 binding domain. STORAGE: Lyophilized — store at -20°C for long-term stability. Reconstituted — use immediately or store at 4°C for short-term. PATIENT EDUCATION: This is a research compound that kills cancer cells by a completely novel mechanism — poking holes in their membranes by targeting a protein (HDM-2) found only on cancer cell surfaces. It is genuinely promising science published in top journals. However, it is years away from clinical availability. No human trials exist. Do not use as a substitute for evidence-based cancer treatment.
Research Summary
TIER 1 (Gold Standard): Kanovsky et al., 2010 — Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes (PNAS, PMID: 20080680). Sookraj et al., 2010 — transfection of membrane-targeted HDM-2 into normal cells renders them PNC-27-susceptible (proof of mechanism). Arouri et al., 2022 — PNC-27, a chimeric p53-penetratin peptide, binds to HDM-2, induces selective membrane-pore formation and leads to cancer cell lysis (Biomedicines, PMID: 35625700). TIER 2 (Strong): Sarafraz-Yazdi et al., 2014 — PNC-27 induces tumor cell necrosis in poorly differentiated leukemia (Annals of Clinical & Laboratory Science, PMID: 25117093). Bowne et al., 2018 — PNC-27 kills cancer cells via mitochondrial disruption (PMID: 38802154). PNC-27 and cervical cancer with ketone body enhancement (European Society of Medicine, 2024). TIER 3 (Moderate): Integrative oncology case reports (anecdotal). Research peptide supplier documentation. Community interest from cancer research forums. KEY FINDINGS: (1) PNC-27 is one of the most cancer-selective peptides ever described. (2) Mechanism is novel and well-characterized (membrane HDM-2 targeting). (3) Works independent of p53 — effective against p53-null cancers. (4) Dual kill mechanism (membrane pores + mitochondrial disruption). (5) Zero clinical data — purely preclinical. GAPS: No human trials. Pharmacokinetics unknown. In-vivo tumor penetration and biodistribution. Optimal delivery method. Manufacturing scalability. ACTIVE TRIALS: None registered on ClinicalTrials.gov.